You cannot register anymore for this webinar

What can Biologics Modelling do for you?

Protein-based drugs are one of the most important classes of therapeutics. Despite this, the field of rational design of biologics remains challenging. Recently, in silico technologies have emerged as valuable tools in both discovery and development.
In this webinar, we will discuss how a range of computational solutions can be used to overcome typical problems in the field including structure prediction, epitope mapping, protein engineering and developability.

In this webinar we will discuss:
  • Protein structure prediction
  • Protein docking/epitope mapping
  • In silico mutagenesis
  • Protein developability


About Schrödinger:
Schrodinger is a provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The company is also applying its computational platform to a robust pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies.
In addition, the company is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs.

More information at www.schrodinger.com 
Presentations by:
Jenny Brookes - Senior Applications Scientist, Schrödinger

Dan Cannon - Senior Applications Scientist, Schrödinger

Moderator: 
Robin Chaudret - Senior Account Manager, Schrödinger

Duration
Presentations: 50 minutes - Q&A: 10 minutes

You can view this webinar from your computer, tablet or mobile phone.

About the presenters:

Jenny Brookes 
received her PhD in Theoretical Condensed Matter Physics at University College London (UCL), UK in 2008. She was then awarded a Sir Henry Wellcome Post Doctoral Fellowship from the Wellcome Trust UK for 4 years. During which she worked at MIT investigating sensing in olfaction and then Harvard investigating efficient photosynthetic processes. Subsequently she moved back to the UK and UCL to join the i-sense – an £11M EPSRC IRC in Early Warning Sensing Systems for Infectious Diseases and Antimicrobial Resistance as the lead theoretical & computational biophysicist investigating protein-protein interactions for optimizing HIV and ‘flu biosensors with respect to sensitivity and selectivity.

Dan Cannon received his BSc (Hons) in Pure and Applied Chemistry from the University of Strathclyde, Glasgow in 2011, where he remained for his PhD, under the supervision of Prof. Tell Tuttle, using various in silico techniques to understand the behavior of peptides in solution and at interfaces. In 2016, he began working at MedImmune in Cambridge UK, using computational approaches for therapeutic protein design before joining Schrödinger in August of 2018 as a Senior Applications Scientist, where he uses his expertise in biologics to support customers in getting the most from the biologics suite and helps them to add substantial value to projects.


Share this webinar